OmniAb, Inc. has entered into a definitive securities purchase agreement for a private placement of its common stock.
The private placement involves the issuance and sale of approximately 21.25 million shares of common stock at $1.40 per share.
Gross proceeds from the private placement are expected to reach around $30 million before deductions for fees and expenses.
Private Placement Details
21,254,106 shares of common stock to be sold at $1.40 per share.
Expected Gross Proceeds
Approximately $30 million anticipated from the private placement.
Use of Proceeds
Net proceeds to be utilized for general corporate purposes.
Participation
Involvement of top-tier investors, officers, and directors in the financing.
Placement Agent
Leerink Partners serving as the sole placement agent for the private placement.
- OmniAb's financing includes a mix of new and existing top-tier investors, enhancing confidence in the company's future prospects.
- The private placement signifies a strategic move to boost the company's capital position for further growth and development initiatives.
OmniAb's successful private placement highlights investor confidence in the company's technology platform and growth potential. The additional capital infusion is expected to propel OmniAb's research and development efforts for next-generation therapeutics.